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Abstract
Identification of biomarkers is an emerging area in Oncology. In this ar-
ticle, we develop an efficient statistical procedure for classification of protein
markers according to their effect on cancer progression. A high-dimensional
time-course dataset of protein markers for 80 patients motivates us for de-
veloping the model. We obtain the optimal threshold values for markers
using Cox proportional hazard model. The optimal threshold value is de-
fined as a level of a marker having maximum impact on cancer progression.
The classification was validated by comparing random components using
both proportional hazard and accelerated failure time frailty models. The
study elucidates the application of two separate joint modeling techniques
using auto regressive-type model and mixed effect model for time-course data
and proportional hazard model for survival data with proper utilization of
Bayesian methodology. Also, a prognostic score has been developed on the
basis of few selected genes with application on patients. The complete anal-
ysis is performed by R programming code. This study facilitates to identify
relevant biomarkers from a set of markers.
Keywords : Classification, Frailty, Joint Modeling, Auto-regressive, Bayesian.
1Corresponding Author
1
ar
X
iv
:1
90
7.
12
85
3v
1 
 [s
tat
.A
P]
  3
0 J
ul 
20
19
1 Introduction
Biomarkers are measurable biological characteristics used as indicators of the oc-
currence and progression of disease. They play a crucial role in identifying disease
onset as well as improving drug development process. The detection of cancer at
primitive stages is based on the identification of deviation of biological character-
istics from the normal status. Thus, potential biomarkers can be identified among
specific proteins or peptides which are evaluated higher or lower in cancer patients
compared to controls.
Protein molecular biomarkers are particularly popular due to their potential for
early detection of disease or providing information about the risk of disease [1]. To
measure cancer progression more effectively, it is required to collect observations
multiple times and hence, circulating biomarkers are becoming more popular in
cancer treatment. Circulating biomarkers identified in biological liquid samples,
termed as liquid biopsies, are particularly important in identification of tumor cells
[2]. There are several advantages of liquid biopsies over tissue-based profiling; they
are minimally invasive, can be sampled repeatedly, collect information efficiently
with less sampling bias and allow longitudinal tracking of patient response to ther-
apies [3].
Gene expression data, acquired from microarray experiments, are increasingly
used to measure changes in the gene expression over time [4], [5]. The analysis of
temporal changes of gene expression is useful to comprehend the complex mech-
anism of gene and its effect on disease progression. One of the critical problems
associated with gene expression data is its high dimensional structure. Single gene
expression data or expressions of only a few genes are easy to analyze. However,
the analysis becomes difficult when the number of gene expressions is high and it
is necessary to accommodate all the genes together in the analysis. Classical sta-
tistical tools fail to analyze such high dimensional gene expression data. There are
several approaches including gene-by-gene statistical analysis, dimension reduction
methods or gene set analysis which acknowledge such kind of data ([6], [7], [8]).
Gene set analysis is an important tool to analyze high-dimensional gene expression
data and also considered to be more powerful than gene-by-gene analysis. It can
detect a change in expression of a group of genes that are functionally linked. The
time-course gene set analysis (TcGSA), which is an extension of gene set analysis,
relies on random effects modeling with maximum likelihood estimates. TcGSA
is a hypothesis-driven method that takes into account the potential heterogeneity
of gene expressions and distinguishes genes with significant temporal variations
in expressions. Other methods adapted and found suitable in analysis of genes
are namely Gene Set Enrichement Analysis, sigPathway, Significance Analysis of
Function and Expression etc [9], [10], [11].
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Figure 1: Flowchart of Clustering Algorithm
In oncology research, the effect of gene expression on the occurrence of death or
disease progression is a challenging area for research and cultivation. For high di-
mensional longitudinal gene expressions data, it is necessary to identify the change
in effect of the gene on an event (disease occurrence or death) and clustering
genes according to that. For longitudinal gene expression data, it is observed that
the measurements are often dependent over previous values, i.e., they are auto-
correlated. The baseline expression value portrays a significant role and often the
recent expression value is compared to the baseline value to draw the necessary
inference [12]. Associating longitudinal gene expressions with the event occurrence
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using joint modeling technique carries significant importance in this kind of study.
The longitudinal process can be explained using an auto-regressive model or stan-
dard mixed effect model. For survival analysis, there are some well-known available
methods like Cox proportional hazard model or accelerated failure time model.
Several approaches have been proposed to analyse longitudinal gene expression
measurements but only a few adddresses high-dimensional gene expression data.
Also there is a clear lack in usage of joint modeling technique in gene expression
study. Also as per the knowledge of authors, there are absolutely no literature on
use of auto-regressive joint modeling in this area of research which is quite obvious
due to the computational difficulty. In this article we present a detailed proce-
dure of joint modeling using both ‘auto-regressive type’ longitudinal model and
standard mixed effect joint model. Bayeain methodology is applied in fitting joint
model. The data is analysed with proper programming code using R opensource
software. R-INLA package is used for survival analysis and joint modeling using
bayesian techniques. In section 2, we explain the filteration method of markers
using proportional hazard model. In section 3, the clustering method is validated
using frailty effect and the protein markers are ranked according to their frailty.
In section 4, we analysed longitudinal data using auto-regressive model. In section
5 and 6, the joint modeling technique is decribed using auto-regressive type lon-
gitudinal model and standard mixed effect model respectively. In section 7, some
discussions are made on our proposed procedure and future scope of this work.
2 Methodology
2.1 Cox Proportional Hazard Model and Filteration :
Analysis based on duration of survival in relation to occurrence of death is consid-
ered as survival analysis. The application of survival analysis has been broadened
in a variety of disciplines with the definition of survival duration and event history.
It stands apart as an useful tool by accomodating the censoring of event due to
non-occurrence. The event of interest is often considered as death which phrases
such terminology to this vast area of study. There is a vast literature available on
survival analysis which has been broadened by a large number of researchers ([13],
[14], [15], [16]). However, very limited literature is devoted towards the develop-
ment of statistical methods for the analysis of multi-level survival data [17]. Frailty
models are also introduced and described to analyse clustered survival data ([16],
[18], [19]). The hierarchical linear model (HLM) was introduced as the primary
method to analyze multilevel data with continuous variables whereas The hierar-
chical generalised linear model (HGLM) was introduced to accommodate discrete
outcomes. However, very limited resources of multi-level analysis is dedicated to
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provide a detailed discussion of multi-level survival analysis with emphasis on ap-
plications using softwares [20].
Suppose that there are n independent subjects (i.e., patients). Let T ′i be the time
to failure for the ith subject, i = (1, ..., n) and Zi is a k × 1 vector of covariates.
The failure time is subject to non-informative right censoring Ci. Also we assume
that ∆i = 0 indicates the failure time is censored and ∆i = 1 indicates the event
observed. So, the failure time Ti is considered as min(T
′
i , Ci). Therefore, the
observed data consists of {Ti,∆i, Zi} for i = 1, ..., n. T ′i and Ci are independent
given Zi for each i.
The hazard fuction for the ith subject is defined as,
λi(t|Zi) = lim
h→0
Pr(Ti ∈ [t, t+ h)|Zi)/h (1)
For each patient, the survival duration is split into several parts based on their
follow-up dates. So for a patient i, the duration is computed only from the last
follow-up. So, the 1st duration is computed as 1st follow-up date to 2nd follow-
up date, 2nd duration is computed as 2nd follow-up date to 3rd follow-up date
and so on. Whenever an event occurs, the duration between last follow-up to the
disease occurrence time is considered. Here it is assumed that the occurrence of
disease greatly influences the gene expression. So, the value of gene expression at
immediate follow-up can be considered as the value of gene expression at the event
occurence time. Hence to calculate time duration, the immediate sampling date
post disease occurrence is ignored and the next duration is taken as the time span
between 2nd immediate follow-up date and disease occurrence date.
Assume that for a patient i, the duration of survival is [0,di] where,
di =

Ci, when there is no event occurrence or,
the event happened in between follow-ups.
T ′i , when the event occurred after the last follow-up
The survival duration of a patient is divided into a few parts based on number
of follow-up. We assume that the number of follow-ups for patient i is li where
the maximum vlaue of li is 4. Let the duration between follow-ups are t1, t2, ..., tli .
The gene expressions are assigned accoreding the above defined procedure. The
survival durations are assumed to be independent.
To analyse survival data, one of the most widely used parametric method is Cox
proportional hazard model (Cox, 1972). For ith individual with jth time point, the
proportional hazard model fitted for a particular gene can be written in simple
terms as,
λij(t|Zij) = λ0(t)exp(Zijβ) (2)
or,
log λij(t|Zij) = log λ0(t) + Zijβ, j = 1(1)li (3)
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where Zij is an indicator function defined as follows. For each gene g at time
point j, j = 1(1)4, the expression values are divided into deciles and we have to
find the optimal threshold value of activity of these genes. For a particular pth
decile [p =1(1)9], the expression is divided into two parts, [min Yg, Y(g,p)] and
[Y(g,p),max Yg].
Zij =
{
0 for Yg,ij < Y(g,p)
1 for Yg,ij ≥ Y(g,p)
In this way, the proportional hazard models that are fitted for different indicators
on time-point j for gene g are,
log λ(tij) = log λ0(tij) + I(Yij > Y(p))
′βj, p = 1(1)9 (4)
For each equation, we obtain a corresponding p-value which demonstrates the
significance of the covariate. Lower the p-value, greater is the significance of the
covariate on response. Here, the equation with minimum p-value gives highest
importance on the indicator which produces the highest significant level of gene
expression. For each time point, we obtain the threshold values of gene expression.
Our interest is to classify the genes according to their effect on the disease occur-
rence. Gene expressions of some particular genes increase with the disease occur-
rence, while for some gene expressions, the disease affects negatively on expressions.
So it is important to take into account the signs of the parameters associated with
the indicator of threshold values. For the kth gene at j time-points, the parameters
obtained using Cox proportional hazard model are [βk1, βk2, ..., βkj]. If βkj > 0 for
all j, then the gene is called Progressive Gene and if βkj < 0 for all j, then the gene
is called Oppresssive Gene. Other than these two type of genes, there are some
other genes which do not have a consistent positive or negative aasociation with
the disease occurrence over time i.e., βkj is neither > 0 nor < 0 for all j. These
genes are called Volatile Genes.
2.2 Frailty Effect in Gene Expression
The frailty is an important aspect to introduce randomness in survival models.
The unobserved heterogeneity that influences the hazard function can be addressed
using a random factor in survival modeling. Earlier the frailty model was denoted
as a survival regression model (either a Cox proportional hazard model or any other
parametric model) that incorporates a random component. Later it is defined as
survival model with only random intercept whereas mixed effect model is used
to refer a model with multiple random effects [21]. Thus, the frailty model is
referred as a special case of mixed effect survival models. Earlier, the subject
specific random effects were primarily adddressed by frailty models to account the
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unmeasured subject characteristics. These models were subsequently extended to
incorporate cluster specific random effects to address within-cluster homogeneity
effect in hazard rate. These models are referred as shared frailty model as the
frailty is shared among all the subjects in same cluster ([16], [18]).
Cox regression models with mixed effects are popularly used to address shared
frailty. Different distributions have been considered for the shared frailty terms
including Gamma distribution, Weibull distribution, Log-normal distribution, pos-
itive stable frailty distributions etc. ([22], [23], [19]). The gamma and log-normal
distributions are most commonly used for frailty terms. The term ’nested frailty
model’ was pioneered by Rondeau et al. to refer survival models with multi-level
clustering [24].
In proportional hazard model, the frailty effect can be associated in the following
way. Let tij be the survival time for the j
th individual in the ith cluster, i =
1(1)n, j = 1(1)mi. Keeping similarity with the notations as defined in proportional
hazard model, we define Cij as the censoring time and Tij as the event time. The
failure time Xij is defined as min(Tij, Cij). Also the censoring indicator is defined
as ∆ij where ∆ij = I(Tij < Cij). Also, we define the no. of observed events as
di =
∑mi
j=1 ∆ij. The frailty model is defined as,
λij(t|wi, Zij) = λ0(t)exp(Ztijβ + wi) (5)
where h0(t) and β is same as defined in proportional hazard model. wi is the
random effect for the ith cluster. Here, wi’s are the actual values of a sample from
density fW . This model can be rewritten as,
λij(t) = λ0(t)uiexp(Z
t
ijβ) (6)
where ui = exp(wi) is the frailty for the i
th cluster.
Another way of adressing frailty in survival model is using accelerated failure time
(AFT) model. With usual notations as mentioned before, the AFT frailty model
is defined as,
SZij(t) = S0(exp(−Z ′ijβ − wi)) (7)
The model can be written as,
log(Tij) = µ+ Z
′
ijβ + ui + σij (8)
where µ is the intercept parameter, ui are cluster specific random effects which are
assumed to be i.i.d. random variable with density function f(ui). Assuming tij
follows a Weibull distribution,
tij|λij ∼ Weibull(α, λij) (9)
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for which the hazard function is,
λ(t) = αλijt
α−1 (10)
which is reduced to exponential hazard for α = 1
For jth gene in the ith cluster with frailty for kth patient, the proportional hazard
frailty model will be,
λij(tk) = λ0(t)exp(Z
t
ijkβ + wij) (11)
The frailty term wij is aasumed to follow a zero-mean normal distribution with
variance γij. The variance term will be used to validate the classification of the
gene clusters. Penalized partial likelihood (PPL) method by Breslow is used for
the estimation of frailty parameter.
2.3 Auto-Regressive Longitudinal Model
In longitudinal study, often the interest lies on the change in observations where
the observations are correlated based on time of sampling. In cross-sectional data,
the value of a response at a particular time-point may depend on its value at
previous time-points. To address this problem, it is required to incorporate an
auto-regressive dependency in modeling.
Efforts have been made to include auto-regressive error structure in mixed effect
model. The most common formulation based on a continuous-valued latent pro-
cess assumes that the individual effects follow an Autoregressive model of order 1
(AR(1)) [25], [26]. This model is referred as Latent Autoregressive (LAR) Model.
Bacci et al. has describeded an auto-regressive time-dependent latent process for
each subject in the LAR model [27]. They proposed a model for longitudinal data
which is based on a mixture of continuous AR(1) processes with different means
and correlation coefficients but equal variances. Models based on discrete latent
process (Latent Markov (LM) model) assume that the individual effects follow a
first-order Markov model. Korn et al. have considered the relation between change
in exposure variables to changes in outcome over time with binary outcomes [28].
In their analysis, the number of time points with information is large relative to the
number of exposure variables. The same authors have also extended this problem
for continuous outcome variables. Rosner et al. used an autoregressive structure
over the responses where the observations at a particular time are linearly depen-
dent over observations on earlier time-points [29]. Conditional distribution of yit
on yi,t−s for ith subject has been discussed for equi-spaced time points which is
later extended to unequispaced time-points [30].
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The Autoregressive model of order 1 for longitudinal data is defined as,
yit = α + γyi,t−1 +
J∑
j=1
βjxijt +
K∑
k=1
β∗kzik + eit (12)
where i=1,2,...,n; t=1,...,T; yit=value of the outcome variable for the i
th individual
at the tth follow-up, xijt=value of the j
th time-dependent covariate for the ith person
at time t. zik=value of the k
th fixed covariate for the ith person, eth are statistically
independent for all i, t with a common distribution N(0, σ2).
2.4 Joint Modeling of Longitudinal and Survival Data
2.4.1 Using Auto-regressive-Type model for longitudinal data
In our study, an ‘Auto-regressive type’ model is fitted to the longitudinal data
where the final outcome is dependent only on the baseline observations. Proper
care is taken to obtain the baseline observationsa which are considered as error-
free. Hence the final observations are compared with the baseline observations to
observe the changes and make necessary infernece on the current status on the
basis of baseline data. So, the model adopted in our study is,
yi,f = α + βyyi,b +Xi,bβl + Zi,bbl + ei
= α +
[
βy βl
] [ yi,b
Xi,b
]
+ Zi,bbl = Mi + ei
(13)
where yi,f is the final observation of the i
th patient, yi,b is the baseline observation
and ei is the subject specific error. Xi,b and Zi,b are the fixed and random covariates
for ith patient at baseline with corresponding coefficients βl and bl. Mi is the true
unknown baseline profile.
The proportional hazard submodel for survival data is defined as,
λij(t) = λ0(t)exp(Z
t
ijβs + γmi) (14)
where γ is the association parameter, Mi(t) = {mi(s), 0 ≤ s ≤ t} is the true
unknown longitudinal profile upto time t. Zij,g is covariates for survival model and
βs is their parameters.
The estimation procedure for joint modeling falls either frequentist approach or
Bayesian approach. Both the approaches use the full joint likelihood derived from
the joint distribution of repeated measurements and time-to-event data. In this
article, our focus was mainly on the Bayesain methodology. The posterior dis-
tributions of the model parameters are derived using the standard Markov Chain
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Monte Carlo Method(MCMC). Here joint modeling as described by [37] will be
followed to perform the necessary analysis. Under this methodology, the sequence
of measurements for the ith subject at times si1, si2, ..., sin is modeled as
yij = µi(tij) +W1i(sij) + ij (15)
where µi(t) = X1i(t)β1 is the mean response and W1i(s) = Z1iUi is the subject-
specific random effects and ij ∼ N(0, σ2 ) is the mutually independent measure-
ment error. The Ui are the vectors of random effects corresponding to the variables
Z1i(s). For the survival part, in a weibull model, the survival time for the i
th sub-
ject follows Weibull(r, µi(t)) where log(µi(t)) = X
t
2iβ2 + W2i(t) and r > 0. The
form of W2i(t) is similar to that W1i(t) with subject-specific covariate effect and
an intercept term, called as frailty. Therefore the weibull survival model is,
λi(t) = rt
r−1exp(X2i(t)β2 +W2i(t)) (16)
In joint model, a zero mean bivariate Gaussian model for (W1i(t),W2i(t))
t is as-
sumed which is independent for different subjects. The joint model links the lon-
gitudinal and survival models by assuming,
W1i(s) = U1i + U2is (17)
and
W2i(t) = γ1U1i + γ2U2i + γ3(U1i + U2it) + U3i (18)
The parameters γ1, γ2, γ3 measures the association between two submodels by as-
sociating random intercepts, slopes and fitted repeated measurement at the event
time W1i(t) respectively. The prior specifications for the parameters are followed
as explaind in [39]. The paired latent variables (U1i, U2i)
t has a zero-mean bivariate
Gaussian distribution N(0,Σ) and U3i, independent of (U1i, U2i)
t are independent
frailty terms modeled as iid N(0, σ23). We have obtained the posteriors distributions
using Expectation-Maximization algorithm and gaussian prior for the parameters
and model selection is performed based on Watanabe-Akaike information criteria
(WAIC) [40].
2.4.2 Using Mixed Effect Model for longitudinal data
Joint modeling is an important tool to accomodate both longitudinal and survival
observations with time-dependent covariates. Both longitudinal and survival mod-
els are associated in a single model with an association parameter to estimate the
effect of baseline covariates as well as time-dependent covariates on the disease
progression. A classical linear mixed effect model is popularly used to address the
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longitudinal study whereas proportional hazard model are widely used for the sur-
vival submodel. Research has been extended to a number of different submodels
for both longitudinal and survival parts whereas different distributions have been
considered for to accomodate various challenges observed in real life data.
In many clinical studies, it is common that both longitudinal measurement data
and time-to-event data are collected during follow-up [31]. This has been an active
research area for the past two decades. The literature on this topic is extensive,
with comprehensive reviews given by [32], [33]. Reviews specific to joint latent class
models and multivariate longitudinal data are given by [34] and [35] respectively.
In joint models, a classical linear mixed effect model is popularly used to specify
longitudinal measurements and Cox proportional hazard model for the survival
part. The mixed effect model for longitudinal measurements is associated inside
the survival model with an link parameter [36], [37], [38].
For analysing longitudinal measurements, one of the most popular tools is mixed
effect model where the response variable is decomposed into two parts, one in-
corporates the fixed effect covariates whereas the other one explains the random
components. The mixed effect model is defined as,
Yij = Mij + ij = Xijβ + Zijb+ ij, ij ∼ N(0, σ2) (19)
where Yij denotes the j
th measure of ith patient, Mij is the true effect of the data or,
the true longitudinal response which we will model in mixed effect model, ij is the
error component attached to the data. Xij & Zij are the fixed effects and random
effects respectively. Also, β & b are the coefficients of fixed effect and random
effects respectively. We assume the measurement error component ij follows a
Normal distribution with mean 0 and variance σ2 and the error is independent of
b. The estimates of the coefficients can be computed using generalized estimating
equations using independent model and also considering unstructured model for
the correlation structure and estimate of the correlation components.
The Cox proportional hazard function is described in equation (14). The joint
model is defined as,
hi(t|Ki,Mij) = h0(t)exp(Kiα +Mijφ) (20)
where Ki denotes the time-independent covariates with coefficients α and φ mea-
sures the effect of longitudinal process on the survival outcome. The longitudinal
submodel is replaced in mit as before with an association parameter and Bayesian
methodology as explained in 2.4.1 is used to obtain posterior distributions of the
parameters.
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2.4.3 Prognostic Score
In survival analysis, it is important to assign a value or score to a patient based
on several factors associated with the survival. This score is generally referred as
Prognostic score. Patinets with complete information of the factors are included
for calculation. Descriptive statistics are evaluated by utilizing Cox proportional
hazard model for this group of patients and survival durations are predicted by the
utilizing the prognostic factors. The scores from each factor are summed into a raw
score for survival prediction. Brier score is one of the popularly used score function
which measures the accuracy of probabilistic predictions. The Brier score is a
weighted average of the squared distances between the observed survival status and
the predicted survival probability of a model. Roughly the weights correspond to
the probabilities of not being censored. Prediction error curves are obtained when
the Brier score is followed over time. Based on the hazard ratio of proportional
hazard model for a particular gene, we compute the contribution of that gene over
the survival of patient. For a new patient, those gene expressions are collected and
their scaled value are multiplied with the percentage contribution which results in
a score value. Those score values are added to get a consolidated score which is a
prognostic score. Based on the prognostics score, we compute Brier score to draw
inference regarding patient survival.
3 Application on Gene Expression Data
3.1 Description of Data
To perform our procedure, we have used a published dataset on Gene Expres-
sion study collected from Gene Expression Omnibus (GEO) database (https:
//www.ncbi.nlm.nih.gov.in/geo/) under the accession number GSE 65622. The
data was first published in April, 2016 and later updated in August 2016. All the
patients were given neoasjuvant chemotherapy (NACT) followed by chemoradio-
therapy (CRT) and treatment evaluation was carried out for four weeks after CRT
completion. After 2-4 weeks, radical pelvic surgery was considered. The study
consists dataset on 80 patients and the observations were obtained in the following
manner. Serum samples were collected at baseline (Sapling point=1), following
NACT post-NACT(Sampling point=2), at CRT completion (Sampling point=3),
post-CRT (Sampling point=4) and at treatment evaluation (Sampling point=5).
With a high-density antibody array (AHH-BLG-1;RayBiotech Inc.), the samples
were analyzed for the presence of 507 proteins. Further explanation about the
study setting and deatiled description of the data can be cited from Meltzer et
al. (2016). The objective of the study is to classify the proteins according to
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their effect on cancer progression and investigate the association between factors
regarding tumor severity and duration of disease reoccurrence.
3.2 Analysis
In the analysis, we define the evnet as a relapse of disease or metastatic disease.
The patients enter the study at different timepoints and observed till a common
censoring data which is 08/08/2013. The interest of the study is to classify the
genes based on their effect on occurrence of local relapse or occurrence of metastatic
disease. In case of occurrence of both the diseases, whichever is earlier is considered
for event occurrence. Here, 1 indicates the occurrence of disease and 0 indicates
non-occurrence. The gene expressions also contain a few missing values which are
not considerd in the analysis.
The occurrence of event is associated with the gene expression and hence it is
required to find the optimal threshold level of activity of gene expression at each
time-point. To achieve that, we randomly classify the gene expression at a time
point into two parts using Deciles e.g., the expressions under pth decile is compared
the expressions above pth decile along with the number of events. The survival
duration is considered as the duration between two sampling points. If the event
occurred in that duration, then the duration is split in two parts. As for example, if
an event occurred in between 2nd and 3rd sampling data, the duration id considerd
as 2nd samplind date to date of occurrence and date of occurrence to 4th sampling
date. For events ocuuring after the last sampling date, the last duration is considerd
as last sampling date to date of occurrence.
The comparison is made based on Cox Proportional Hazard. The CoxPH is ap-
plied on the two random parts created based on deciles and the p-values of the
model is compared for different deciles. The threshold with lowest p-vlaue indi-
cates the optimal threshold value of gene expression for event occurrence. During
the formation of parts, it is required to keep an eye on the number of events in
the partitions. So, we consider a minimum of 3 event occurrences in each of the
partition. Thus for 4 time-points, we obtain 4 threshold values with minimum p-
values at each time-point, minimum frailty values and corresponding coefficients.
Based on the threshold values and coefficients obtained of the gene expressions,
the Progressive, Regressive and Volatile genes are classified. We obtain 86 Progres-
sive genes, 16 Regresssive genes and 404 Volatile genes. The correlation network
diagram of the genes for different clusteres are plotted in figure 3.
We consider both PH and AFT model to obtain the frailty terms for each gene.
The patient-speific frailty term is assumed to follow zero-mean Gaussian distribu-
tion. The weibull distribution is considered for the response y i.e. log Ti. Compar-
isons are made on the basis of the histograms of variance component of the random
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effects for 3 clusteres. It is found that the sd of the frailty components for both tha
model are quite similar. The coefficient of variations of the starand deviations for
each clusteres are also calculated for comparisons. We ranked the genes based on
the variance of the random components obtained in frailty models. The results are
shown in table 1 and 2. It is evident that for both the clusters, there are several
genes which fall in the top 10 under both AFT and PH frailty. From the histogram
plots of standard deviations of frailty components shown in figure 4, we can find a
clear distinguish between the patterns of Progressive and Regressive genes. In plot-
ting the histogram for Progressive genes, one gene has frailty variance of 17.625.
To get a clear picture of the pattern, that gene is omitted from the plot.
In the next stage, we fit joint models using auto-regressive-type model for longi-
tudinal data and proportional hazard model for time-to-event data for each gene
expressions. In medical context, it is important to correlate the final outcome with
the baseline observations as the baseline responses are considered to be mostly
error-free. The diagnosis of disease and gene classification is better associated
with the baseline observations. We consider all those observations for which the
baseline observations are present and there are atleast 2 longitudinal observations
are found. For modeling of longitudinal observations of each gene, we considered
only the baseline observation and final outcome for a patient. The survival duration
is considered as the duration till occurrence of event or censoring. The covariates
considered were T-stage (0 - tumor not found, 1-4 - Size of the tumor, higher
the number, greater the size), N-stage (the number of nearby lymph nodes that
contains cancer. Higher the value, larger the spread) and TRG-score (Tumor Re-
gression Grading Score. 0 - Complete Regression, 5- Absence of Regression). Thus
we fit a Bayesian joint model with auto-regressive type longitudinal model with
gaussian response and weibull survival duration with r=1 using R-INLA. Among
different fitted models, the best model chosen on the basis of WAIC is,
yij = β11 + β12sij + β13 × (t stage)i +W1i(sij) + ij (21)
where W1i(sij) = U11i + U12isijand
log(µi) = β21 + β22 × (t stage)i +W2i(t) (22)
where W2i(t) = γ1U11i + γ2U21i + γ3(U12i + U22it) + U3i. The prior distribution of
U11i and U21i is specified as N
(
0,
(
3 10
10 0
))
and the prior distribution of U11i
and U21i is specified as N(0, 0.01).
The same is performed for mixed effect longitudinal model also using t-stage
and n-stage for longitudinal covariates and t-stage for survival covariate. Among
different fitted models, the best model chosen on the basis of WAIC is,
yij = β11 + β12sij + β13 × (t stage)i +W1i(sij) + ij (23)
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where W1i(sij) = U11i + U12isijand
log(µi) = β21 + β22 × (t stage)i +W2i(t) (24)
where W2i(t) = γ1U11i + γ2U21i + γ3U12i +U3i. The prior specifications are followed
same as previous. The results for both joint models is shown in table 3.
We conside 10 genes from each of the Progressive genes and regressive genes based
on the minimum frailty for calculation of prognostics scores. The contributions
of genes on the survival is also computed using hazard ratio of Cox proportional
hazard model shown in table 4. 12 patients with complete information was obtained
and 5 of them have experienced the event. The prognostic scores of those patients
are calculated as shown in the table and based on that, we obtain the Brier plot
2. 4 different Cox models are compared to obtain the best prediction model. The
covariates considered for the models are (i) Both progscore 1 and progscore 2
(Reference) (ii) only progscore 1 (Cox Model 1), (iii) only progscore 2 (Cox Model
2), (iv) the sum value of progscore 1 and progscore 2 (Cox Model 3). The progscore
1 denotes score based on only the Progressive Genes and progscore 2 denotes score
based on only the Regressive Genes. It is evident from the figure that the Cox
model based on only the Progressive genes have the lowest prdiction error among
them.
4 Discussion and Conclusion
Identification of biomarkers is an important aspect in oncology research. Early de-
tection of cancer is crucial to initiate treatment at early stages and improve overall
survival rate. Currently the tissue-based biopsy, which has a potential detrimen-
tal effect on patients, is typically used for detection of tumor. So, plasma/serum
biomarkers are becoming more popular due to their potential in cancer screen-
ing and minimal-invasive nature. There are several available methods to detect
biomarkers which have the potential to diagnose disease progression and for ac-
curate prognosis. In most of the times, it is found that those analyticaly sound
biomarkers fails to pass proper validation tests in medical process. As a result,
though there are a number of procedures available for biomarker detection, a very
few number of markers are really promoted to achieve the ‘status’ of biomarker.
The problem becomes more challenging for high-dimensional data.
In this article, we described an efficient statistical procedure of filteration method
and ranking of the protein markers based on their effect in disease progression
from high-dimensional data. We identified a few protein biomarkers and further
explained the use of different types of joint modeling using those biomarkers to
present the applicability of our work. It is pivotal to identify the nature of influence
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of protein markers on overall survival. However, due to the data-driven approach,
there is always a chance of plausible randomness in the modeling. In this study,
we developed a proper statistical algorithm which produces clustering of genes
based on their effect on disease progression and also ranking of genes based on the
presence of random component when information of a large number of markers are
available. Also, we assigned prognostic scores to few selected patients based on the
contribution of identified biomarkers on survival outcome.
There are good scopes for further improvements that can be carried out on the
proposed procedure. The proposed ‘auto-regressive type’ joint modeling can be
refined more efficiently. Several distributional assumptions can be considered for
responses and parameters to accommodate different medical situations. Also the
methodology can be extended for binary marker responses. There is an excellent
scope of refinement in the filteration method using different survival models and
accommodating different types of censoring methods. The procedure can be further
extended for competeing risks to consider multiple events of interest in context of
survival. Also, use of bayesian methodology in the clustering algorithm can be an
interesting area of study.
In conclusion, the next generation of liquid biopsy studies is crucial for establishing
clinical applicability of blood-based cancer diagnostics and improvement of survival
rates. We are optimistic that the proposed methodology for discovery of new
biomarkers will decrease the cost of treatment and will show the light for better
methods to detect disease at more treatable stages.
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Figure 2: Brier plot for different prognostic models
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(a) Correlation Network on Progressive Genes 1-20 alphabetically
(b) Correlation Network on Regressive Genes
Figure 3: Correlation Network of Progressive and Regressive Genes. Red for neg-
ative correlation and green for positive correlation. The thickness defines strength
of correlation
21
(a) For Proportional Hazard Model
(b) For Accelerated Failure Time Model
Figure 4: Histogram of satndard deviation of frailty component obtained using two
different models. Cluster 1,2 and 3 represents Progressive, Regressive and Volatile
Genes respectively.
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Table 1: Coeffcients of fitted AFT model and Standard Deviation of random com-
ponents of top 10 Markers according to ascending order of randomness (a) For
Progressive genes (cluster=1), (b) For Regressive Genes (cluster=2)
Gene Name Gene No. intercept
coefficient of
expression value
sd of
AFT frailty
range sd/range cluster
TGF-beta RIII 455 9.001 -0.024 0.831 79.722 0.010 1
DAN 93 9.188 -0.012 1.010 343.947 0.003 1
APJ 20 9.597 -0.011 1.148 242.469 0.005 1
S100 A8/A9 418 9.346 -0.001 1.191 2974.719 0.0004 1
Lymphotactin / XCL1 330 9.340 -0.007 1.245 385.803 0.003 1
GDF3 171 9.219 -0.001 1.314 13525.530 9.72e-05 1
NRG3 383 8.714 -0.000 1.315 26532.430 4.96e-05 1
GREMLIN 192 8.473 -0.000 1.359 17648.610 7.70e-05 1
TFPI 446 8.303 -0.002 1.388 213.524 0.006 1
Ubiquitin+1 492 8.150 -0.000 1.391 22814.850 6.09e-05 1
Gene Name Gene No. intercept
coefficient of
expression value
sd of
AFT frailty
range sd/range cluster
Eotaxin / CCL11 117 7.857 0.001 1.440 2127.944 0.001 2
Activin RIB / ALK-4 6 7.878 0.001 1.451 2417.925 0.001 2
Frizzled-4 158 7.746 0.002 1.512 762.211 0.002 2
IL-3 291 7.571 0.001 1.518 1587.440 0.001 2
IL-2 R gamma 275 7.650 0.002 1.524 1122.739 0.001 2
IL-22 BP 282 7.690 0.001 1.528 1756.997 0.001 2
IL-31 293 7.846 0.001 1.581 3417.479 0.001 2
IL-2 R beta /CD122 274 7.865 0.001 1.596 680.924 0.002 2
Insulin 307 8.266 -9.32e-05 1.632 3613.603 0.001 2
GDF1 169 8.790 -0.001 1.864 734.911 0.003 2
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Table 2: Coeffcients of fitted PH model and Standard Deviation of random com-
ponents of top 10 Markers according to ascending order of randomness (a) For
Progressive genes (cluster=1), (b) For Regressive Genes (cluster=2)
Gene Name Gene No.
coefficient of
expression value
sd of
PH frailty
range sd/range cluster
TGF-beta RIII 455 0.024 0.410 79.723 0.010 1
MMP-19 360 0.005 0.619 4269.286 0.000 1
Dkk-3 98 0.006 0.634 441.068 0.003 1
CLC 71 0.003 0.635 507.079 0.003 1
S100 A8/A9 418 0.001 0.677 2974.719 0.001 1
GREMLIN 192 0.000 0.692 17648.610 7.70e-05 1
DAN 93 0.011 0.697 343.947 0.003 1
TLR4 472 0.009 0.764 522.589 0.003 1
Lymphotactin / XCL1 330 0.007 0.779 385.803 0.003 1
APJ 20 0.010 0.802 242.470 0.005 1
Gene Name Gene No.
coefficient of
expression value
sd of
PH frailty
range sd/range cluster
Activin RIB / ALK-4 6 -0.001 0.900 2417.925 0.001 2
Eotaxin / CCL11 117 -0.001 0.943 2127.944 0.001 2
IL-2 R gamma 275 -0.001 1.071 1122.739 0.001 2
IL-22 BP 282 -0.001 1.074 1756.997 0.001 2
IL-3 291 -0.001 1.096 1587.440 0.001 2
Insulin 307 -0.001 1.133 3613.603 0.001 2
IL-31 293 -0.001 1.134 3417.479 0.000 2
Frizzled-4 158 -0.002 1.172 762.211 0.002 2
IL-2 R beta /CD122 274 -0.001 1.200 680.924 0.002 2
FGF-12 135 -0.001 1.201 2917.189 0.001 2
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Table 3: Bayesian Joint Model output for longitudinal and survival model. The
first table shows for auto-regressive-type longitudinal model and the second table
shows for mixed effect longitudinal model. For both the cases, exponential survival
model has been used
mean sd 0.025 Quantile 0.5 Quantile 0.975 Quantile
Intercept (β11) 22.057 6.629 9.041 22.056 35.061
Intercept(β21) -12.831 5.118 -22.686 -12.818 -2.954
baseline covariate (β12) 0.723 0.078 0.570 0.722 0.875
Precision for the Gaussian observations 10562.321 58.357 10448.069 10562.153 10677.637
Precision for U11 (component 1) 0.001 0.000 0.001 0.001 0.001
Precision for U11 (component 2) 0.006 0.000 0.006 0.006 0.006
Covariance(ρ12) for U11 -0.110 0.002 -0.113 -0.109 -0.106
Precision for U3 (σ2) 65.726 33.222 6493.662 6558.638 6624.353
Precision for U12 -0.011 0.001 -0.013 -0.011 -0.009
Precision for U22 -1.958 0.003 -1.964 -1.958 -1.951
mean sd 0.025 Quantile 0.5 Quantile 0.975 Quantile
Intercept (β11) 0.048 0.385 -0.708 0.048 0.8046
Intercept(β21) -1.986 0.573 -3.114 -1.985 -0.8636
time (β12) 0.012 0.137 -0.257 0.012 0.2815
t stage (β13) 0.030 0.119 -0.204 0.030 0.2638
n stage (β14) 0.040 0.226 -0.403 0.04 0.483
t stage (β22) -0.125 0.172 -0.463 -0.125 0.2109
Precision for the Gaussian observations 0.000 0.000 0.000 0.000 0.000
Precision for U11 (component 1) 0.001 0.000 0.001 0.001 0.001
Precision for U11 (component 2) 0.003 0.000 0.003 0.003 0.003
Covariance(ρ12) for U11 0.944 0.001 0.942 0.946 0.946
Precision for U3 (σ2) 132.752 2.255 128.345 132.744 137.214
Precision for U12 -1.242 0.015 -1.273 -1.242 -1.213
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Table 4: Percentage Contribution on Survival of patients by prognostic genes using
Progressive genes (cluster=1) and Regressive Genes (cluster=2)
Gene Name
Threshold
Value
Regression
Coefficient
Range
Minimum
Value
Cluster Hazard Ratio
Percentage
Contribution
APJ 87.917 0.524 242.470 35.445 1 1.005 0.099
DAN 46.968 0.698 129.225 27.347 1 1.014 0.100
GDF3 3260.853 0.299 13525.530 726.510 1 1.000 0.099
GREMLIN 1152.626 1.060 17648.610 395.198 1 1.000 0.099
Lymphotactin / XCL1 132.482 0.333 264.899 70.644 1 1.007 0.099
NRG3 1226.503 1.022 26396.300 508.641 1 1.001 0.099
S100 A8/A9 613.560 0.606 2315.253 369.818 1 1.001 0.099
TFPI 40.688 1.018 164.217 19.129 1 1.004 0.099
TGF-beta RIII 56.306 1.211 60.818 13.441 1 1.057 0.105
Ubiquitin+1 346.890 0.694 7658.155 220.388 1 1.000 0.099
Activin RIB / ALK-4 393.051 -0.566 1825.192 214.306 2 0.999 0.100
Eotaxin / CCL11 162.370 -0.495 2127.944 95.435 2 0.999 0.100
Frizzled-4 182.803 -0.297 762.211 72.907 2 0.997 0.100
GDF1 476.263 -0.470 674.048 127.1591 2 0.999 0.099
IL-2 R beta /CD122 219.408 -0.631 538.898 162.753 2 0.998 0.100
IL-2 R gamma 200.761 -0.593 1095.012 115.514 2 0.999 0.100
IL-22 BP 633.122 -0.407 1678.951 168.434 2 01000 0.100
IL-3 341.101 -0.717 1394.570 226.991 2 0.999 0.100
IL-31 293.513 -0.348 3093.107 61.015 2 0.998 0.100
Insulin 1452.828 -0.526 2959.707 191.915 2 0.999 0.099
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